Jade Biosciences Inc.
09/09/2025 | Press release | Distributed by Public on 09/09/2025 05:13
Management Change/Compensation (Form 8-K)
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective September 9, 2025, Hetal Kocinsky, M.D. departed from her position as Chief Medical Officer of Jade Biosciences, Inc. (the "Company"). The Company expects to enter into a separation agreement with Dr. Kocinsky. Under the separation agreement, subject to the Company's receipt of a general release of claims against the Company, Dr. Kocinsky will receive (i) a one-timepayment equal to 12 months of her current base salary and (ii) a cash payment equal to the premiums payable by Dr. Kocinsky for continuation coverage under COBRA for a period of 12 months.
The Company's scientific and clinical programs will continue to be led by Dr. Andrew King, Ph.D, Chief Scientific Officer and Head of Research & Development.
The foregoing description of the separation agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the separation agreement, a copy of which the Company intends to file as an exhibit to a future report under the Exchange Act after the execution of the separation agreement.
Jade Biosciences Inc. published this content on September 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 09, 2025 at 11:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]